TGFBR2 and breast carcinoma: The in silico simulation results indicated that high levels of E2F1–TGFBR1–FGFR1 in bladder cancer and E2F1–TGFBR2–EGFR in breast cancer constitute a molecular signature that represent the most aggressive phenotype.